Home / Market News / $VBIO

$VBIO news and market catalysts

The 7 most recent market catalysts affecting $VBIO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 0 high impact 3 bullish 0 bearish Biotechnology
Oct 15, 2026 Corporate Catalyst Neutral Impact 55
Valion Bio's Velocity Biowork Subsidiary Completes Initial Feasibility Evaluation Of LarmorBio's BioScan-NMR Platform
Valion Bio's wholly-owned subsidiary, Velocity Bioworks, successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform. This platform aims to introdu…
Oct 14, 2026 Corporate Catalyst Neutral Impact 55
Valion Bio Announces Velocity Bioworks' Capabilities To Support Biotechnology Firm Mulling U.S.-Based Production For Biologics Programs
Valion Bio is highlighting the capabilities of its wholly-owned CDMO, Velocity Bioworks, to support other biotechnology companies looking for U.S.-based manufacturing for early-pha…
Sep 30, 2026 Corporate Catalyst Bullish Impact 65
VBIO stock has given up its prior gain. Valion Bio shares were trading higher after the company announced the completion of formulation work under the company's ongoing program to develop a novel oral mucosal formulation of Entolimod with Shear Kershman Laboratories.
The headline indicates a corporate catalyst – the completion of formulation work for a novel drug. While this is a positive development for Valion Bio, the fact that the stock has …
Sep 23, 2026 Corporate Catalyst Neutral Impact 75
Valion Bio Appoints Dean Zikria Interim CEO, Thomas Jensen As Board Chair
Valion Bio has announced a significant shake-up in its executive leadership and Board of Directors. Dean Zikria, a current board member, has been appointed Interim CEO, tasked with…
Aug 27, 2026 Corporate Catalyst Neutral Impact 65
Valion Bio Announces 1-For-25 Reverse Stock Split, Effective Aug. 31
Valion Bio announced a 1-for-25 reverse stock split, effective August 31, 2026, to meet the Nasdaq Capital Market's minimum bid price requirement. This action, while necessary to m…
Jul 22, 2026 Corporate Catalyst Bullish Impact 65
Ukraine's Ministry Of Health Accepts Valion Bio's Regulatory Dossier For Entolimod For Formal Review Under Regulatory Equivalence Pathway
Valion Bio announced that Ukraine's Ministry of Health (MoH) has accepted its regulatory dossier for Entolimod, a medical countermeasure for Acute Radiation Syndrome (ARS), for for…
Jul 20, 2026 Corporate Catalyst Bullish Impact 65
Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer Participants
Valion Bio (VBIO) has announced a significant clinical development: a collaboration with Sheba Medical Center to conduct a clinical trial for Entolimod in cancer patients undergoin…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.